2015-consumption-did-47.html
DANMAP 2015 3D
48 / 144
danmap
2015
48 antimicrobial consumption
in humans 5. clavulanic acid for the treatment of respiratory tract infections led to changes in ddd from 2g to 1g per day but probably no noteworthy changes in the recommended duration of treatment the 2015 distribution of the leading antimicrobial classes is shown in figure 5.3. beta-lactamase sensitive penicillins
represented the largest therapeutic group of antimicrobial agents consumed, constituting 26% of the consumption. penicillins in general (including combinations with beta-lacta- mase inhibitors) accounted for 65% of the total consumption. macrolides accounted for 11%, tetracyclines for 10%, sulfon- amides and trimethoprim for 4%, nitrofurantoin and fluoro- quinolones for each 3% (figure 5.3). a decade ago, in 2006, beta-lactamase sensitive penicillins accounted for 35%, penicillins with extended spectrum for 19% and macrolides for 15%. tetracyklines accounted for 9%, beta-lactamase resistant penicillins for 8%, sulfonamides and trimethoprim for 6%, nitrofurantoin for unchanged 4%, fluorquinolones for unchanged 3% and combination penicillins for only 1% (dan- map 2006, not shown). beta-lactamase sensitive penicillins (j01ce) ; 26% penicillins with extended spectrum (j01ca) ; 22% macrolides, lincosamides and streptogramins (j01f) ; 11% tetracyclines (j01aa) ; 10% beta-lactamase resistant penicillins (j01cf) ; 8% comb. of penicillins, incl. beta-lactamase inhib. (j01cr) ; 9% sulfonamides and trimethoprim (j01e) ; 4% fluoroquinolones (j01ma) ; 3% other antibacterials (j01d,g,x, p01ab) ; 7% fig 5.3 figure 5.3. distribution of the total consumption of antimicrobial agents in primary health care, denmark danmap 2015 0 1 2 3 4 5 6 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 ddd/1000 inhabitant-days beta-lactam. sens. penicillins (j01ce) penicillins with extend. spectrum (j01ca) macrolides (j01fa) tetracyclines (j01aa) beta-lactam. resis. penicillins (j01cf) fluoroquinolones (j01ma) combinations of penicillins, including beta-lactamase inhibitors (j01cr) fig 5.2 figure 5.2. consumption of leading antimicrobial groups for systemic use in primary health care, denmark danmap 2015
patient-ddds-packages-49.html
